* If you want to update the article please login/register
"Background: The modified systemic to pulmonary artery shunt is an effective palliative therapy in children with cyanotic congenital heart disease that are not suitable for total correction. " Using bovine mesenteric venous graft and polytetrafluoroethylene, the aim of this study was to compare the clinical results and rate of graft failure in cyanotic infants with hereditary thrombophilia using bovine mesenteric venous graft and polytetrafluoroethylene. Methods: 60 cyanotic patients with thrombophilic risk factors were divided into two groups: BMVG and PTFE. Protein C and S deficiency, and Factor V Leiden mutation were two of the most common thrombophilic factors, according to the most common thrombophilic factors, along with Factor V Leiden mutation. In 2 patients in the BMVG group and 8 patients in the PTFE group, early thromboses were found in both patients and 8 patients in the PTFE group. Following an acute thrombosis of BMVG that has been documented before [Cil 2010], a successful percutaneous balloon angioplasty has been performed by Cil et collegues. We performed transluminal graft angioplasty in another patient with acute BMVG thrombosis in the catheterization lab using a good thrombolytic procedure. In three patients within 24 hours, thrombosis caused by PTFE. In infants with partial or complete PTFE occlusion in 5 patients, Transluminal balloon angioplasty combined with thrombolysis was administered in infants with partial or total occlusion. In the early period after surgery, we performed revision surgery due to bleeding from the needle hole in three patients in the PTFE group's early period. In 1 patient 6 months after surgery in the PTFE group, we discovered a graft infection. In the BMVG group, there was no evidence of thrombosis or shunt occlusion, but 5 patients in the PTFE group had shunt occlusion during follow-up. ".
Source link: https://doi.org/10.1532/hsf.2749
"Hereditary thrombophilia is a multifactorial disease that is mono- or plurigenic, and its clinical manifestation is correlated with a heterogeneous word. " Factor V Leiden and FII gene mutations are more common than antithrombin, and protein C and S deficiencies are more frequent than antithrombin. Heterozygous carriers of FV Leiden or FII gene mutation have a reduced risk of venous thrombosis. Mutation cosegregation dramatically raises the risk of thrombosis. Both mutations have a geographic and ethnic distribution in connection with a gene founder effect. Generally, deep or superficial thrombosis with or without pulmonary embolism, thrombosis, thromboses at rare locations, or with an elevated risk of fetal loss and abortion are among the most common features of fetal loss and abortion. Some protein S and FII gene mutations seem to be restricted to arterial thromboses. Other unindentified gene mutations, at least partially, are likely explanations of hereditary thrombophilia's heterogeneous expression.
Source link: https://doi.org/10.1159/000022491
"Aim : To determine the effectiveness of using low molecular weight heparin and low-dose acetylsalicylic acid in patients with early and late fetal growth retardation in patients with antiphospholipid syndrome and/or genetic thrombophilia. " By using enzyme immunoassay methods, the Sydney antiphospholipid syndrome tests were determined according to the Sydney antiphospholipid syndrome criteria: cardiolipin, u03b22-glycoprotein 1 and other antibodies to annexin V, prothrombin, etc. In 7 pregnant women, in two weeks, in 2 at 20 and 22 weeks, in 3 weeks after 34 weeks of pregnancy, FGR re-developed in 7 pregnant women in 7 weeks, in 2 at 30 and 22 weeks. The use of LMWH and low-dose ASA from the early pregnancy period and early pregnancy as part of complex therapy has been able to effectively prevent FGR re-development in patients with thrombophilia. In the case of elevated titers, the use of LMWH and low-dose ASA may be ineffective, and alternative treatment strategies in lieu of anticoagulant therapy should be used to achieve obstetric outcomes.
"Prior research on thrombophilia as a risk factor for DAVF development in DAVF research is limited due to small sample sizes and poor generalizability. " METHODS The University of California, San Francisco, where intracranial DAVFs were evaluated from December 1994 to April 2014 were identified in this longitudinal observational study. Results The study involved a total of 116 patients with confirmed intracranial DAVFs. Focal neurological disorders tended to arise more frequently in the thrombophilia group. DAVFs had a more pronounced thrombosis pattern, increased risk of venous flow pattern, multiplicity of DAVF, and the presence of venous sinus thrombosis in the thrombophilic group than in the nonthrombophilic group, but not so prevalent in the thrombophilic group than in the nonthrombophilic group. In this analysis, the incidence of mutations related to thrombophilia was greater than in the general population. ".
Source link: https://doi.org/10.3171/2017.10.jns171987
"Coronavirus 2, a severe acute respiratory syndrome coronavirus 2, may cause a similar imbalance. " In COVID-19, activation of coagulation and thrombocytopenia appeared as prognostic markers. Since the state of hypercoagulation is directly related to COVID-19 and thrombotic events, we suggest that research into the genetic structure of proteins involved in thrombophilia in patients with COVID-19 and thrombotic events is of utmost importance, both in treating and preventing deaths due to COVID-19.
Source link: https://doi.org/10.3390/healthcare10060993
"Most patients with thrombophilia are asymptomatic. " This is a picture of a young woman with protein S deficiency, one of the thrombophilias, who required dental extraction. Low-molecular-weight heparins are highlighted, a brief review of thrombophilia is provided, and the care of patients who are taking warfarin and need dental surgery is addressed. ".
Source link: https://doi.org/10.12968/denu.2000.27.6.302
"Genetic testing for thrombophilic gene mutations is performed using a variety of techniques including real-time polymerase chain reaction and DNA microarrays of specific genes. " "The main aim of this narrative review was to quantitatively evaluate the literature on the specific treatment of pregnant women with thrombophilia who are at risk of developing unplanned miscarriages. ".
Source link: https://doi.org/10.3390/medicina58050692
"The patient suffered from related vomiting and anorexia for 48 hours before admission. " Upon admission, the abdominal pain had gotten more severe and spread to both flanks. A deep vein thrombosis had occurred 18 months before he died, according to his medical history. He was taking Tegretol for epilepsy and asthma inhalers. The umbilical and epigastric regions were tenderly examined during an abdominal examination. Laparoscopy revealed symoanguinous fluid and gangrenous loops of small bowel. Laparotomy announced the presence of a 24u201d gangrenous segment of distal jejenum and proximal ileum. Perioperatively, this segment was found to have good arterial pulsation with apparent clot in the venous arcades. Histology announced a mesenteric infarction by Histology. A thrombophilia screen was staged in light of the previous history of deep vein thrombosis. Our patient was a heterozygous positive for the factor V leiden mutation," according to our family's "Western family member" with the factor V leiden mutation. ".
Source link: https://doi.org/10.12968/hosp.2000.61.10.1450
"Summary": "The emergence of venous thromboembolism, which includes deep-vein thrombosis and pulmonary embolism, may be connected to genetic or acquired risk factors that can be determined in plasma or DNA testing. A number of other abnormalities have been less consistently associated with an elevated risk of VTE screening, except these established biomarkers, which usually refer to the first-level laboratory tests for thrombophilia screening.
Source link: https://doi.org/10.1160/th15-06-0478
"The authors discuss their experience and approach to diagnosing and treating patients with heterozygotic factor V Leiden thrombophilia undergoing free flap reconstruction. " Methods Between November 2009 and June 2018, 23 free flap surgeries were performed in 15 hypercoagulable patients with hFVL. HFVL mutations had been reported preoperatively in 14 free flap surgeries, but in nine free flap surgeries, mutations were only diagnosed postoperatively, requiring further hypercoagulability work-up after the occurrence of microvascular thromboses had been anticipated. The overall rate of intraoperative flap thromboses was 9%, but the overall rate of postoperative flap thromboses was 43 percent. Conclusions "Meticulous preoperative work-up of patients with a history of hypercoagulability can help reduce free flap loss rates, thus improving surgical outcomes and raising patient safety. ".
Source link: https://doi.org/10.1186/s12893-022-01639-3
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions